IL17A and breast carcinoma: They showed anticarcinogenic effects in breast tumors, mainly by ameliorating some pro-inflammatory cytokines IL-17, IL-2, IL-12, IFN-γ, and TNF-α, in addition to improving DTH and NK responses, decreased tumor volume, and prolonged survival in breast cancer animal model.